Neurology
Frontotemporal Dementia
33
Pipeline Programs↗
9
Active Trials↗
16
Companies Involved↗
Frontotemporal Dementia is a moderately active landscape with 33 programs across 16 companies. The most active players are Retrophin, Pfizer, Eli Lilly. 6 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 14
Phase 217
Phase 33
Analysis
Trial Status
33
clinical trials
Completed16 · 48%
Recruiting4 · 12%
Terminated3 · 9%
Active, not recruiting3 · 9%
Unknown status2 · 6%
Withdrawn2 · 6%
Other3 · 9%
Clinical Trials
Trial Activity
33 trials
Nabilone for Agitation in Frontotemporal Dementia
Recruiting·—·Phase 2·NCT05742698·45 enrolled
Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
Not yet recruiting·—·Phase 2·NCT07154485·15 enrolled
Oxytocin and Social Cognition in Frontotemporal Dementia
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT01002300·24 enrolled
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
Completed·—·Phase 3·NCT00594737·17 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)